SES •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 08/24/2026 17:11
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeSES
Market Capitalization546.66 mln
Float621 mln
Earnings Date08/24/2026
Piotroski F-Score
5
/ 9
Neutral
Relative Strength
1
/ 100
Severely lagging
Debt / Equity
0.35
Low leverage
ROE
-36.47
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
iX Biopharma is a Singapore-based pharmaceutical and nutraceutical company that develops and sells treatments for pain, sexual health, mental health, metabolic conditions, and general wellness across Singapore, the United States, China, and Australia. The company is best known for its sublingual wafer technology, which delivers active ingredients through the lining of the mouth, and its product range spans both prescription medicines and consumer health supplements. Founded in 2004, iX Biopharma has several products already on the market and a broad pipeline of candidates at various stages of clinical development, including treatments for depression, obesity, diabetes, chronic pain, and respiratory illness.